Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
30-week once-daily RO7795081 vs placebo and oral semaglutide in type 2 diabetes mellitus
2024-520322-11-00Phase 2Authorised
- Sponsor
- Roche
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of RO7795081 in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Roche. Primary endpoint: Change in HbA1c from baseline at Week 30 (primary). Planned start Sep 2025; status: authorised.
02
Drugs
RO7795081
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2024-520322-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520322-11-00.